The results of this study will provide a basis for the clinical use of SGLT2 inhibitors and the management of blood lipids in patients with type 2 diabetes mellitus when taking these drugs, so as to better control blood glucose smoothly and prevent the occurrence of related complications. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.